Diabetic amyotrophy …

Peripheral Neuropathies

Updated 01.29.2024
Released 01.16.2007
Expires For CME 01.29.2027

Diabetic amyotrophy

Authors: Aziz I Shaibani MD, Duaa Jabari MD

See Contributor Disclosures

Editor: Louis H Weimer MD

Diabetic amyotrophy

In This Article

Quick Link

Introduction

Overview

Diabetic amyotrophy is predominantly a motor condition that involves various elements of the lumbosacral plexus, particularly those related to the femoral nerve. It usually presents acutely as unilateral thigh pain followed by weakness and later wasting in the anterior thigh muscles. Diabetic amyotrophy typically occurs in older patients with type 2 diabetes. An immune-mediated epineurial microvasculitis has been demonstrated in nerve biopsies. When severe and progressive, predominantly motor polyneuropathy develops in diabetic patients, one must also consider chronic inflammatory demyelinating polyradiculoneuropathy. In this article, the authors discuss studies that have provided novel insights into the pathogenesis of diabetic amyotrophy, leading to the establishment of formal clinical trials of mechanistically relevant therapies like immunoglobulin and methylprednisolone.

Key points

	• Diabetic amyotrophy, which usually presents as unilateral thigh pain followed by weakness, can be painless.
	• The diabetic amyotrophy mechanism is ischemic injury, possibly secondary to microvasculitis.
	• It is important, and sometimes difficult, to differentiate diabetic amyotrophy from chronic inflammatory demyelinating polyradiculoneuropathy.

Historical note and terminology

The syndrome of wasting and weakness of the pelvifemoral muscles associated with diabetes mellitus was originally described by Ludwig Bruns in 1890 (07). Many years later, Garland and Taverner expanded the description (21) and later coined the term “diabetic amyotrophy” (20). Since the inception of the term, its nomenclature has been controversial based on its variable presentations (proximal vs. proximal and distal; asymmetric vs. symmetric), onset (abrupt vs. insidious), and different electrophysiological and biopsy findings described. Skeptics have challenged the term “diabetic amyotrophy” because it erroneously implies a primary muscle disorder as well as the term “proximal diabetic neuropathy” because distal weakness is often present as well. Disagreements regarding pathogenesis (metabolic vs. ischemia) have prompted some authors to suggest that the process is a clinical continuum of diabetic neuropathy rather than a distinct clinical entity (02). Similarities to other symptom complexes have produced newer and more descriptive terms such as “diabetic lumbosacral radiculoplexus neuropathy” and “diabetic mononeuritis multiplex.” Considerable evidence that diabetic amyotrophy is a distinct clinical entity with a defined clinical spectrum and pathophysiology has emerged over the last several years.

Clinical manifestations

Presentation and course

Diabetic amyotrophy is a disabling neuropathy that usually occurs in patients with type 2 diabetes mellitus in middle or later age. Concomitant weight loss is frequent. Patients usually have not had diabetes for a long time, and glycemic dysregulation is often not severe. Interestingly, a diagnosis of diabetic amyotrophy leads to the discovery of underlying diabetes mellitus in one quarter to one third of cases. Long-term diabetic complications such as diabetic retinopathy and nephropathy are often absent at the time of diagnosis. The clinical presentation is characterized by sudden, sharp, and asymmetric pain that usually starts in one hip and thigh and subsequently spreads to the other side within weeks to months (04; 03; 09). Cases of worsening over 18 months are described (03). Weakness starts distally in one third of cases, leading to unilateral or bilateral foot drop. As the pain improves, weakness becomes the major symptom; it affects both proximal and distal leg muscles.

Diabetic amyotrophy

This video clip demonstrates proximal and distal leg muscle weakness and atrophy in two patients of diabetic amyotrophy. (Video used with permission from the Nerve and Muscle Center of Texas.)

In about one third of cases, weakness spreads to proximal arm muscles and is attributed to cervicobrachial radiculoplexopathy (39; 13; 27). However, some of these upper extremity deficits result from compression neuropathy from reliance on the arms to support body weight. Approximately 12% of patients develop thoracic radiculopathy, leading to radiating belt-like chest or abdominal pain and intercostal muscle weakness causing pseudohernia (53; 30; 51; 50).

Diabetic truncal radiculopathy

Video clip demonstrating weakness of thoracic and abdominal muscles in a patient of diabetic amyotrophy. (Video used with permission from the Nerve and Muscle Center of Texas.)

Prominent bulbar symptoms have been described (10). Respiratory weakness may also be the initial manifestation of diabetic proximal neuropathy (06).

Diabetic amyotrophy can be painless. Graces-Sanchez and colleagues studied 23 patients (22 had type 2 diabetes mellitus) who developed painless, lower-limb, motor-predominant neuropathy. The clinical features were similar to diabetic amyotrophy, except painless patients had more symmetrical and upper limb involvement with slower evolution. They compared the nerve biopsy findings of these patients with the pathological features of 33 painful diabetic amyotrophy biopsies and 25 chronic inflammatory demyelinating polyradiculoneuropathy biopsies. The nerve biopsy findings of these patients were similar to the findings in classic painful diabetic amyotrophy but not CIDP (23).

Prognosis and complications

The weakness initially worsens over weeks or sometimes months, although the pain resolves earlier. With disease progression, half of the patients become wheelchair-bound, and almost all require assistance with ambulation. Progression may continue up to 18 months from onset. Recovery usually occurs spontaneously but is slow and often incomplete. Although only 9% of patients need a wheelchair after 2 years, only 10% of patients achieve a full recovery in the same time period. Relapses on the same or other side occasionally occur.

In a population-based study comparing patients with diabetic and nondiabetic lumbosacral radiculoplexus neuropathy (LRPN) to age and sex-matched control group, patients with lumbosacral radiculoplexus neuropathy had lower median survival (12.2 years for the lumbosacral radiculoplexus neuropathy group vs. greater than or equal to 17 years for the control group), which translated to 76% increased risk of death. This increased risk of death was related to the comorbidities found in the lumbosacral radiculoplexus neuropathy group and not the lumbosacral radiculoplexus neuropathy itself (40).

Clinical vignette

A 58-year-old diabetic man on an oral hypoglycemic treatment developed sudden severe pain that started in the lower back and radiated to the right leg. After 3 days, he experienced weakness in the same leg. After 45 days, similar pain and weakness occurred in the left leg. Symptoms persisted for 4 months, during which time the patient had a 10 kg unintentional weight loss. Neurologic examination revealed asymmetric proximal and distal weakness in both legs. There was atrophy of the quadriceps and hamstring muscles. A stocking pattern of loss of pinprick, light touch, and vibration sense was found. Tendon reflexes were absent at the ankles and decreased at the knees bilaterally. Upper extremities had normal motor and sensory function.

At the initial evaluation, fasting glucose was mildly elevated (136 mgs/dl), with a normal glycosylated hemoglobin of 6.8%. Peroneal motor conduction velocity was reduced at 36 m/s, and compound motor action potential was reduced at 300µV. Tibial nerve conduction was 38 m/s, and sural potentials were unobtainable. Median and ulnar nerve conduction velocities were normal. An EMG revealed denervation potentials in proximal (quadriceps and hamstrings) and distal (gastrocnemius and anterior tibial) muscles bilaterally. A sural nerve biopsy revealed an asymmetric loss of myelinated fibers and microvasculitis with endoneurial mononuclear cell infiltration.

His recovery was protracted. He required a knee brace for ambulation and was treated with tricyclic antidepressants for pain. Leg weakness progressed for 3 additional months before subsequent gradual improvement of strength. At the 6-month follow-up (10 months into the disease), the pain had almost resolved. However, he still had considerable residual weakness.

Biological basis

Etiology and pathogenesis

As the term “diabetic amyotrophy” indicates, this disorder was classically linked to diabetes mellitus. In an epidemiology study, diabetes was found to be the most common risk factor for radiculoplexus neuropathy, followed by autoimmune disorder, stroke, and higher BMI (41). The most common associated autoimmune disorders in this study were autoimmune thyroiditis, inflammatory bowel disease, and type 1 diabetes mellitus, which could be metabolic risk factors as well. The study conclusion was that “altered metabolism and immune dysfunction seem to be the most influential factors in the development of lumbosacral radiculoplexus neuropathy.” Other risk factors and triggers may also be at play. For example, a case of radiculoplexus neuropathy after COVID-19 infection (42) and another one after mRNA vaccine (08) have been reported, suggesting an immune-mediated process.

Although metabolic derangement is considered the main mechanism of the generalized diabetic neuropathies, a vascular mechanism is suggested to explain the acute onset and focal nature of the focal and multifocal diabetic neuropathies.

Clinical differences between diabetic polyneuropathy and diabetic amyotrophy suggest that they have different mechanisms and pathogenesis.

Table 1. Clinical Differences Between Diabetic Amyotrophy and Diabetic Polyneuropathy

	Diabetic amyotrophy	Diabetic polyneuropathy
Onset	Subacute or acute	Insidious
Symmetry	Asymmetric	Symmetric
Site	Proximal first	Distal
Weakness	Early	Late
Pain	Severe	Variable
Course	Progressive	Gradual
Outcome	Spontaneous improvement	No improvement
DM control	Good	Variable
End organ damage	Uncommon	Common
DM type	Type II	Both types
(Table used with permission from the Nerve and Muscle Center of Texas.)

A vascular process is suggested to explain the clinical picture of subacute, painful, asymmetric neuropathy with weight loss and the multifocal axonal neuropathy evident from the EMG. Raff and colleagues documented multiple areas of nerve ischemia within the lumbosacral plexus in a postmortem study (43). They also reported perivascular inflammation, but there was no pathological indication of vasculitis. Barohn and colleagues confirmed the ischemic damage by studying 10 nerve biopsies showing multifocal nerve loss (03); there was no comment on the presence of inflammation. Said reported the result of 10 cutaneous femoral nerve biopsies from patients with diabetic amyotrophy; ischemic lesions were found in three patients and vasculitis in two (45).

Diabetic microangiopathy and necrotizing vasculitis

Upper panel: Thionine blue-stained section of nerve showing an endoneurial capillary with thickened wall and red cell (R) seepage in the endoneurium. Note the marked reduction in density of myelinated nerve fibers. Lower panel: He...

In another series, vasculitis was found in three of 14 femoral cutaneous nerve biopsies from patients with diabetic amyotrophy (34). Dyck studied 33 patients with diabetic amyotrophy and found multifocal fiber loss in 19 biopsies, perineurial thickening in 24, and neovasacularization in 21 (13).

Multifocal fiber degeneration and loss

Transverse semithin epoxy sections of sural nerve. Upper panel: Low-magnification view showing that most fascicles are devoid of myelinated fibers whereas other fascicles are more intact. Lower panel: Higher-power view of the area...

These studies suggested that the mechanism of injury was ischemic vasculopathy.

What is the cause of ischemic vasculopathy in diabetic amyotrophy? Chronic hyperglycemia and the resulting advanced tissue glycation end-products alone do not fully explain the pathogenesis because most patients with diabetic polyneuropathy do not develop this syndrome despite worse underlying glycemic regulation than that of diabetic amyotrophy patients. Population-based studies show that diabetic amyotrophy groups have better glycemic control, use less insulin, are more likely to have type 2 diabetes mellitus, have been diabetic for a shorter period of time, and have less vascular complications than the diabetic polyneuropathy group (12).

Alternatively, the primary event may be an inflammatory (probably immune) attack against the wall of the endoneurial blood vessels.

A lesson from non-diabetic lumbosacral radiculoplexus neuropathy. Comparison between diabetic and non-diabetic lumbosacral radiculoplexus neuropathy reveals striking similarities, suggesting that diabetes mellitus is a risk factor rather than a cause (11; 14).

Ischemic injury in diabetic and non-diabetic lumbosacral plexus neuropathy

Transverse paraffin sections of sural nerves showing changes seen in diabetic and non-diabetic lumbosacral radiculoplexus neuropathy. Upper panel: Masson's trichrome stain, showing inflammation in the wall of an epineurial microve...
Microvasculitis in diabetic and non-diabetic lumbosacral radiculoplexus neuropathy

Changes characteristic of microvasculitis in non-diabetic lumbosacral radiculoplexus neuropathy (left column) and in diabetic lumbosacral radiculoplexus neuropathy (right column). Upper panels: mononuclear cell infiltration of the...

The similarities also support the vascular and inflammatory nature of the disease as opposed to the metabolic factors.

Diabetic and non-diabetic lumbosacral radiculoplexus neuropathy comparison

The chart compares diabetic and non-diabetic lumbosacral radiculoplexus neuropathy. (Used with permission from the Nerve and Muscle Center of Texas.)
Diabetic and non-diabetic lumbosacral radiculoplexus neuropathy clinical comparison

The chart is a clinical comparison of diabetic and non-diabetic lumbosacral radiculoplexus neuropathy. (Used with permission from the Nerve and Muscle Center of Texas.)

Table 2. Comparison Between Diabetic and Non-Diabetic Lumbosacral Radiculoplexus Neuropathy

Mean value	DLRPN	LRPN
Age: years	65	69
Sex: male-to-female ratio	60%	51%
Onset to bilateral: years	3.0	3.0
Weight change: pounds	-30	-15
CSF protein: mg/ml	89	66
Pain at onset	81%	85%
Foot weakness	36%	36%
Thigh weakness	54%	57%
Wheelchair dependence	48%	49%
Walker or cane usage	42%	49%
Multifocal degeneration	57%	65%
Perivascular inflammation	100%	100%
Mural inflammation	45%	51%
Hemosiderin in macrophages	57%	53%
(Table used with permission from the Nerve and Muscle Center of Texas.)

Evidence of inflammation in pathological studies. In a study that included 12 patients with diabetic amyotrophy, the sural nerve demonstrated a mononuclear cell infiltrate in four patients and a perivascular infiltrate of activated T-cells expressing both interleukin-2 and major histocompatibility complex class II antigens in six patients (33).

Microvasculitis in sural nerve

Serial skip paraffin sections of a microvessel above (upper panels), at (middle panels), and below (lower panels) the region of microvasculitis in the sural nerve of a patient with lumbosacral radiculoplexus neuropathy. The sectio...

However, there was no evidence of B-cells or polymorphonuclear cells. The majority of nerves from patients also showed staining for tumor necrosis factor, interleukin-6, and interleukin-1beta. Furthermore, C3d and C5b-9 complement proteins were found within the endoneurial and epineurial blood vessel walls in all patients (33). In a biopsy study, Kelkar and colleagues described small-vessel neutrophilic vasculitis with polymorphonuclear infiltration in postcapillary venules along with IgM deposition and complement deposition in endoneurium and in affected vessel walls (29).

These studies support that proximal diabetic neuropathy has an immune-mediated and inflammatory basis and suggest that polymorphonuclear vasculitis with immune complex and complement deposition may be the primary event in the acute phase of proximal diabetic neuropathy. Up-regulated specific inflammatory mediators, such as intercellular adhesion molecule-1 in vessels and tumor necrosis factor-alpha in Schwann cells and some macrophages, may be involved in an immune-mediated inflammatory process that is shared by both the diabetic and non-diabetic variants (28).

Dyck studied 33 sensory nerve biopsies from diabetic amyotrophy patients and compared them to biopsies from patients with diabetic polyneuropathy and to biopsies from healthy controls.

Nerve biopsy pathological analysis--diabetic amyotrophy and diabetic polyneuropathy

The chart illustrates a pathological analysis of nerve biopsies from patients with diabetic amyotrophy, diabetic polyneuropathy and healthy controls. (Used with permission from the Nerve and Muscle Center of Texas.)

Table 3. Pathological Analysis of Nerve Biopsies From Patients With Diabetic Amyotrophy, Diabetic Polyneuropathy, and Healthy Controls

Pathology	Diabetic amyotrophy (%)	Diabetic polyneuropathy (%)	Control (%)
N	33	21	14
Multifocal fiber loss	63	42	0
Focal perineurial thickening	80	42	28
Perivascular inflammation	100	28	14
Individual cells (less than 10)	0	23	14
Mild (11 to 50 cells)	64	5	0
Moderate (51 to 100)	21	0	0
Severe (more than 100)	15	0	0
Mural inflammation	45	0	0
Hemosiderin in macrophages	57	0	0
Neovascularization	64	5	7
(Table used with permission from the Nerve and Muscle Center of Texas.)

He found perivascular inflammation in all nerves sampled, mural invasion (microvasculitis) in half, and hemosiderin-laden macrophages in half. The latter finding indicates previous bleeding (13).

The notion of ischemic injury from microvasculitis was further supported by Said’s findings of necrotizing vasculitis of perineurial and endoneurial blood vessels in six of 22 and perivascular inflammation in 21 of 22 nerve biopsies from diabetic amyotrophy patients. He also found endoneurial red blood cells in 11, endoneurial hemorrhage in five, and ferric deposits (a sign of previous bleeding) in seven of these 22 biopsies. In contrast, nerve biopsies from 30 patients with severe distal diabetic polyneuropathy demonstrated only mild epineurial mononuclear cell infiltration in one biopsy and endoneurial red blood cells in one other (46).

Interestingly, muscle biopsies from Said’s 22 patients displayed inflammatory infiltrate in three cases and vasculitis in one case. The lack of fibrinoid necrosis of the vessel wall in all the mentioned series as opposed to the systemic vasculitis may be due to the very small size of the involved vessels in the former.

Diabetic amyotrophy, thus, may be a form of nonsystemic vasculitis isolated to peripheral nerves. However, it remains elusive why small vessels are more susceptible in this condition.

The offensive antigen. The cause of inflammation in diabetic amyotrophy remains intriguing. An immune reaction against the altered walls of small endoneurial blood vessels is possible. The cause of such alteration may be diverse. The association of inflammation with atherosclerosis is increasingly recognized.

After initiation of an atherogenic diet, patches of arterial endothelial cells express selective adhesion molecules on their surface that bind to various classes of leukocytes. The types of vascular cell adhesion molecules (CAM-1) that bind lymphocytes and monocytes in experimental atheroma have been shown in experimental rats (37; 32; 47).

Another possibility is that hyperglycemia modifies macromolecules by forming advanced glycation end-products, and that is shown to augment the production of cytokines (26; 36; 35); but again, patients with diabetic amyotrophy have less vascular complications and better diabetes control than patients with diabetic polyneuropathy, yet microvasculitis is not a feature of the latter. Furthermore, the presence of the same pathology in a non-diabetic suggests an alternative mechanism rather than hyperglycemia and atherosclerosis.

Differential diagnosis

	(1) Systemic vasculitis: polyarteritis nodosa and other rheumatologic, vasculitic, and collagen vascular disorders
	(2) Isolated peripheral nerve vasculitis: the second most common cause of vasculitic neuropathy after polyarteritis nodosa and rheumatoid arthritis
	(3) Chronic inflammatory demyelinating polyradiculoneuropathy
	(4) Compressive lumbosacral plexus lesions (tumors, trauma, hematoma, etc.)
	(5) Quadriceps myopathies (inclusion-body myositis, dystrophinopathies, etc.)

Chronic inflammatory demyelinating polyradiculoneuropathy in diabetes mellitus. The diagnosis of CIDP in diabetic patients represents a dilemma because of many shared features between diabetic polyneuropathy and CIDP, making the application of the CIDP diagnostic criteria less reliable.

Some diabetics present with progressive, painless, symmetrical, proximal, and distal weakness of all extremities evolving over weeks to months and associated with diffuse areflexia or hyporeflexia. Physical examination also shows stocking and glove sensory impairment, which can be explained by diabetic polyneuropathy. CSF protein is frequently elevated, and electrodiagnostic studies meet the American Academy of Neurology research criteria of CIDP, except for some axonal features that are attributed to diabetic polyneuropathy (01). Although the magnitude of response to treatment is not as robust as that seen in idiopathic-CIDP, these cases share more features with CIDP than diabetic polyneuropathy.

Ongoing issues about CIDP development in diabetic patients.

	(1) Is the CIDP purely coincidental?
	(2) Is it a form of diabetic polyneuropathy?
	(3) Is it a painless variety of diabetic amyotrophy?
	(4) Are diabetics at a higher risk of CIDP than others?

Sharma and colleagues studied the frequency of CIDP in patients seen in an EMG laboratory over a 14-month period: 1127 patients were seen; 189 of them were diabetic with various neuromuscular disorders, of whom 32 (16.9%) met the American Academy of Neurology criteria for CIDP. Among the remaining 938 patients without diabetes mellitus, 17 (1.8%) had idiopathic CIDP (49). The odds of occurrence of diabetes mellitus and CIDP were 11 times higher among diabetics than non-diabetics.

CIDP in diabetic and non-diabetic patients

The chart compares chronic inflammatory demyelinating polyradiculoneuropathy in diabetic and non-diabetic patients. (Used with permission from the Nerve and Muscle Center of Texas.)

Does diabetes mellitus CIDP differ from idiopathic CIDP in response to therapy? Sharma and colleagues treated 26 diabetics who met the American Academy of Neurology criteria for CIDP with intravenous immunoglobulins; 21 of them had significant improvement in their neurologic deficit at the end of 4 weeks of therapy (48).

Haq compared 10 nondiabetic patients who met the American Academy of Neurology criteria for CIDP to nine patients with diabetes mellitus and CIDP. The clinical, neurophysiological, and histological features of both groups were similar. Six patients with diabetes mellitus-CIDP and eight patients with idiopathic-CIDP were treated with prednisone with or without intravenous immunoglobulins, plasmapheresis, or azathioprine. All patients responded favorably to the treatment in a similar fashion (24).

Gorson compared the clinical, electrophysiological, and pathological features of 14 patients with diabetes mellitus-CIDP with 60 patients with CIDP. The two groups were similar, except that the sural nerve action potentials were more often absent in the former group, and axonal loss in the nerve biopsy was more frequent (22).

The response rate to treatment with different modalities was also similar (Table 5), except that the magnitude of functional recovery was greater in idiopathic-CIDP as measured by mean strength score, medical research council score, and Rankin disability score.

Table 5. Response of DM-CIDP and I-CIDP to Treatments

Modality	Diabetes Mellitus CIDP	Idiopathic CIDP
IVIG	44	56
TPE	20	44
Steroids	60	41
(Table used with permission from the Nerve and Muscle Center of Texas.)

Caution is recommended in diagnosing CIDP in diabetic patients. Mandatory American Academy of Neurology research criteria for the diagnosis of CIDP is not ideal or practical (Table 6).

Table 6. American Academy of Neurology Research Criteria for the Diagnosis of CIDP

(1) Progressive or relapsing motor and sensory dysfunction of more than one limb of a peripheral nerve nature, developing over 2 months
(2) Diffuse hypo- or areflexia
(3) CSF cells count less than 10/mm if HIV negative, negative VDRL
(4) Unequivocal evidence of demyelination and remyelination in nerve biopsy
(5) Three of four electrodiagnostic criteria found in at least two nerves:
	(A) Decreased nerve conduction velocity less than 80% if amplitude is more than 80% of normal
	(B) Partial conduction block (more than 20% drop)
	(C) Prolonged distal latencies greater than 125% if amplitude is greater than 80% of normal
	(D) Prolonged F-wave greater than 120% if amplitude is greater than 80% of normal
	Definite diagnosis: clinical, electrodiagnostic, CSF, and biopsy criteria Probable diagnosis: clinical, electrodiagnostic, and CSF criteria. Possible diagnosis: clinical and electrodiagnostic criteria.

Conclusions about CIDP in diabetes mellitus.

	(1) Demyelinating features are common in diabetic polyneuropathy (neurophysiologically and pathologically)
	(2) Elevated CSF protein is frequent in diabetic patients.
	(3) Some patients with diabetic polyneuropathy meet the AAN criteria for CIDP.

Therefore, better and more specific criteria are needed and better consideration should be given to the following features that are more consistent with CIDP than diabetic polyneuropathy:

	(1) Proximal and symmetric weakness
	(2) Progressive course
	(3) Diffuse areflexia
	(4) Conduction block at sites not prone for compression
	(5) CSF protein elevation more than 100 mg/mL

A therapeutic trial with steroids, intravenous immunoglobulin, or plasmapheresis may be necessary to distinguish between the two in more diagnostically challenging cases.

Diagnostic workup

The history and physical examination, supplemented by laboratory and neurophysiological findings, usually lay the groundwork for a diagnosis of diabetic amyotrophy.

Laboratory findings. In any case of lumbosacral plexopathy, laboratory studies should include a complete blood count, chemistries, coagulation profile, erythrocyte sedimentation rate, hemoglobin A1c, and fasting blood sugar; if necessary, a 2-hour glucose tolerance test is advocated by many. In diabetic amyotrophy, cerebrospinal fluid protein is frequently elevated (44 to 214 mg/dl), suggesting extension of the disease process to the nerve roots. The erythrocyte sedimentation rate may be raised in patients with proximal diabetic neuropathy (05; 54). Appropriate imaging of the lumbosacral spine, lumbosacral plexus, and pelvis is indicated to exclude compressive etiologies. However, results must be interpreted with caution because incidental abnormalities are common, in particular lumbosacral spondylosis.

MRI has been utilized in many neuromuscular disorders, including lumbosacral radiculoplexus neuropathy. Different findings have been reported, including T2 hyperintensity and enhancement of the lumbosacral roots, plexus, and nerves. T2 hyperintensity of the affected muscles, as can be seen with denervation, is also reported (19). In addition, compared to controls, cross-sectional area of the lumbosacral roots and the femoral nerves is significantly enlarged in diabetic amyotrophy (25). These changes are not specific to lumbosacral radiculoplexus neuropathy, including diabetic amyotrophy, but some or all of these changes can be seen with other disorders (demyelinating polyneuropathies, radiculitis secondary to viral illness, sarcoid, etc.). In the authors’ opinion, the main benefit of the MRI is to exclude certain possibilities, such as severe degenerative spinal disease, benign or malignant compressive lesions, and others, but MRI findings are not specific enough to be helpful in the diagnosis of diabetic amyotrophy.

Neurophysiologic findings. Nerve conduction studies usually reveal marked reduction of compound muscle action potential amplitudes of affected motor nerves in a very asymmetrical fashion. Sensory nerve action potentials show low amplitude or, more frequently, absent responses in the affected regions (13). Mild slowing of nerve conduction velocities is seen (52). These neurophysiologic findings indicate multifocal axonal degeneration rather than demyelination. Needle examination shows spontaneous activity, reduced recruitment of motor unit potentials, and long duration and high amplitude motor unit potentials in muscles supplied by multiple nerve roots and different peripheral nerves, further supporting the occurrence of axonal pathology (44). Paraspinal muscles are usually affected. The EMG abnormalities tend to be much more prevalent and widespread than the clinical picture suggests. In patients with underlying diabetic sensory polyneuropathy, in addition to the above findings, sural sensory nerve action potentials are usually absent, and peroneal and tibial compound motor action potential amplitudes are reduced.

Histologic findings. Biopsies are rarely indicated. Early in the disease course, epineurial and perivascular inflammation around the small vessels may be caused by infiltration by mononuclear cells, with or without polymorphonuclear cells (13). Endoneurial and subperineurial IgM deposition has been reported (29). Activated complement (C5b-9) deposition in the endothelium of small vessels was demonstrated by Krendel (33). A decrease in the number of myelinated and unmyelinated axons may be observed. Differential fascicular loss of axons is also characteristic.

Multifocal fiber degeneration and loss

Management

Treatment is centered initially around pain control. Agents that are commonly used for pain control include non-steroidal anti-inflammatory agents (eg, ibuprofen, naproxen), tricyclic antidepressants (eg, amitriptyline, imipramine), antiepileptics (eg, phenytoin, carbamazepine, gabapentin), and opioids (eg, codeine phosphate, morphine elixir). Mexiletine, an antiarrhythmic, has been used effectively in treating neuropathic pain in several clinical trials. Other allied pain treatments include transcutaneous electronic nerve stimulation, hypnosis, relaxation training, biofeedback, and acupuncture.

Good glycemic control is of paramount importance. Oral hypoglycemic agents may need to be changed to insulin therapy. Meal planning and exercise may be beneficial.

Neurologic recovery is slow. Walking regularly or using elastic stockings may help with leg pain. The physical therapist can assist in improving functional mobility (eg, transfers, ambulation). Assistive devices may be employed when necessary. An exercise and range-of-motion program supervised by the physical therapist is also helpful in maintaining and improving function and avoiding contractures. The occupational therapist can recommend appropriate adaptive equipment (eg, reacher, elevated toilet seat, tub bench), depending on the amount of weakness, so that the patient can be independent in activities of daily living and perform self-care tasks in a seated position.

The pathological findings discussed prompted several investigators to treat diabetic amyotrophy as an inflammatory syndrome. In addition, a favorable response of the non-diabetic lumbosacral radiculoplexus neuropathy to intravenous methylprednisolone in one trial suggests that its diabetic counterpart may respond similarly (14; 15; 17). In this clinical trial, intravenous methylprednisolone was administered to 11 patients with non-diabetic lumbosacral radiculoplexus neuropathy over 8 to 16 weeks. All treated patients had marked improvement in pain and weakness, and pain resolved completely in many. The median neuropathy impairment score (NIS) and neuropathy symptoms and change (NSC) statistically improved after treatment.

Response to methylprednisone in non-diabetic lumbosacral radiculoplexus neuropathy

(Chart used with permission from the Nerve and Muscle Center of Texas.)

Before treatment, half of the patients were wheelchair-bound, and all patients but one used walking aids. After treatment, only one was in a wheelchair, and six walked independently.

The lack of a control arm makes conclusions at best preliminary; the following observations suggest benefit from treatment:

	(1) Pain and weakness improved with initiation of therapy in all cases.
	(2) The improvement was dramatic.
	(3) All patients reported worsening prior to treatment.
	(4) All patients improved after treatment.
	(5) Those who worsened after discontinuation of treatment responded well to reinstitution of therapy.

Therapeutic trials in diabetic amyotrophy. Said treated two patients with diabetic amyotrophy and biopsy-proven vasculitis with prednisone; both had a favorable outcome. Krendel treated 15 patients: seven with intravenous immunoglobulin and prednisone, five with intravenous immunoglobulin alone, two with prednisone and cyclophosphamide, and one with prednisone alone; all improved, five markedly (33). Kilfoyle reviewed the records of nine patients with diabetic amyotrophy treated with steroids and compared them with untreated patients; of the treated group, 75% improved within 1 month, whereas only 59% of the untreated patients eventually improved and none before 6 months. In seven of 10 episodes, pain resolved within 3 months of onset, in contrast with natural history in which pain typically persists for more than 6 months (31). Pascoe treated 12 diabetic amyotrophy patients with prednisone, intravenous immunoglobulin, or plasmapheresis and compared the outcome with 29 untreated patients. The treated group improved faster and to a greater extent (39). Rapid recovery of diabetic lumbosacral radiculoplexus neuropathy after administration of intravenous immunoglobulin has been reported (18).

In a prospective, randomized, double-blind, multicenter controlled trial by Dyck and associates, two thirds of patients received intravenous methylprednisolone (initially 1 gram several times per week, with decreasing doses and frequency over 12 weeks), and the other one third received placebo in a dose of 1 gram three times a week followed by less frequent doses over 12 weeks. The patients were followed for 2 years. Preliminary results from the first year of this trial reveal a significant improvement of mean NIS in both groups. The primary outcome measure (improvement of NIS in lower limbs by 4 points) showed no difference between groups. However, a secondary neuropathic pain symptom outcome measure showed greater improvement that lasted 6 months in the methylprednisolone group (16).

Anecdotal reports of dramatic improvement in neurologic function (38) have resulted in the initiation of a monocenter clinical trial of intravenous immunoglobulin; the study had three arms: high dose, low dose, and control groups. The study was put on hold because of a lack of intravenous immunoglobulin supply.

Conclusions.

	(1) Diabetic amyotrophy localizes to a process at the level of nerve roots, plexus, trunks, and peripheral nerves in a patchy distribution.
	(2) Clinical, neurophysiologic, and pathological findings suggest that the insult is axonal, possibly from nerve ischemia resulting from microvasculitis.
	(3) Noncontrolled trials provide preliminary evidence that immunomodulation may enhance pain relief, speed recovery, and improve outcome, but controlled trials are needed.
	(4) Because the treatment outcome is not clearly better and because of the side effects of steroids and intravenous immunoglobulin, these treatments may only be considered in severe and progressive cases.

Media

References

01: Anonymous. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991;41(5):617-8. PMID 2027473
02: Asbury AK. Proximal diabetic neuropathy. Ann Neurol 1977;2:179-80. PMID 617563
03: Barohn RJ, Sahenk Z, Warmolts JR, Mendell JR. The Bruns-Garland syndrome (diabetic amyotrophy) revisited 100 years later. Arch Neurol 1991;48:1130-5. PMID 1953396
04: Bastron JA, Thomas JE. Diabetic polyradiculopathy: clinical and electromyographic findings in 105 patients. Mayo Clin Proc 1981;56:725-32. PMID 7311600
05: Bradley WG, Chad D, Verghese JP, et al. Painful lumbosacral plexopathy with elevated erythrocyte sedimentation rate: a treatable inflammatory syndrome. Ann Neurol 1984;15:457-64. PMID 6329073
06: Brannagan TH, Promisloff RA, McCluskey LF, Mitz KA. Proximal diabetic neuropathy presenting with respiratory weakness. J Neurol Neurosurg Psychiatry 1999;67:539-41. PMID 10486409
07: Bruns L. Ueber neuritische Lähmungen beim diabetes mellitus. Berliner Klinische Wochenschrift 1890;27:509-15.
08: Coly M, Balcerac A, Brasseur N, et al. Subacute monomelic radiculoplexus neuropathy following Comirnaty (Pfizer-BioNTech COVID-19) vaccination: a case report. Rev Neurol (Paris) 2023;179:636-9. PMID 36925320
09: Coppack SW, Watkins PJ. The natural history of diabetic femoral neuropathy. Q J Med 1991;79:307-13. PMID 1852856
10: Di Biagio F. L'amiotrofia diabetica (con un caso personale di amiotrofia bulbare a tipodi SLA). Rivista di Neurologia 1959;29:457-70.
11: Dyck PJ, Engelstad JN, Norell J, Dyck PJ. Microvasculitis in nondiabetic lumbosacral radiculoplexus neuropathy (LSRPN): similarity to the diabetic variety (DLSRPN). J Neuropathol Exp Neurol 2000;59:525-38. PMID 10850865
12: Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43(4):817-24. Erratum in: Neurology 1993;43(11):2345.
13: Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology 1999;53:2113-21. PMID 10599791
14: Dyck PJ, Norell JE, Dyck PJ. Methylprednisolone may improve lumbosacral radiculoplexus neuropathy. Can J Neurol Sci 2001a;28(3):224-7. PMID 11513340
15: Dyck PJ, Norell JE, Dyck PJ. Non-diabetic lumbosacral radiculoplexus neuropathy. Natural history, outcome and comparison with the diabetic variety. Brain 2001b;124:1197–207. PMID 11353735
16: Dyck PJ, O'Brien PC, Bosch EP, et al. Results of a controlled trial of IV methyprednisolone in diabetic lumbosacral radiculplexus neuropathy (DLRPN): a preliminary indication of efficacy. J Periph Nerv Syst 2005;10(s1):21.
17: Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve 2002;25:477-91. PMID 11932965
18: Fernandes Filho JA, Nathan BM, Palmert MR, Katirji B. Diabetic amyotrophy in an adolescent responsive to intravenous immunoglobulin. Muscle Nerve 2005;32(6):818-20. PMID 15991252
19: Filosto M, Pari E, Cotelli M, et al. MR neurography in diagnosing nondiabetic lumbosacral radiculopathy. J Neuroimaging 2013;23(4):543-4. PMID 23750469
20: Garland H. Diabetic amyotrophy. BMJ 1955;2:1287-90. PMID 13269852
21: Garland H, Taverner D. Diabetic myelopathy. Br Med J 1953;1(4825):1405-8. PMID 13042281
22: Gorson KC, Ropper AH, Adelman LS, Weinberg DH. Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2000;23(1):37-43. PMID 10590404
23: Graces-Sanchez M, Laughlin RS, Dyck PJ, et al. Painless diabetic motor neuropathy: a variant of diabetic lumbosacral radiculoplexus neuropathy. Ann Neurol 2011;69(6):1043-54.
24: Haq RU, Pendlebury WW, Fries TJ, Tandan R. Chronic inflammatory demyelinating polyradiculoneuropathy in diabetic patients. Muscle Nerve 2003;27(4):465-70. PMID 12661048
25: His R, Poh F, Bryarly M, Xi Y, Chhabra A. Quantitative assessment of diabetic amyotrophy using magnetic resonance neurography – a case-control analysis. Eur Radiol 2019;29(11):5910-9. PMID 30980123
26: Jakus V, Rietbrock N. Advanced glycation end products and the progress of diabetic vascular complications. Physiol Res 2004;53(2):131-42. PMID 15046548
27: Katz JS, Saperstein DS, Wolfe G, et al. Cervicobrachial involvement in diabetic radiculoplexopathy. Muscle Nerve 2001;24:794-8. PMID 11360263
28: Kawamura N, Dyck PJ, Schmeichel AM, Engelstad JK, Low PA, Dyck PJ. Inflammatory mediators in diabetic and non-diabetic lumbosacral radiculoplexus neuropathy. Acta Neuropathol 2008;115(2):231-9. PMID 18064475
29: Kelkar P, Masood M, Parry GJ. Distinctive pathological finding in proximal diabetic neuropathy. Neurology 2000;55:83-8. PMID 10891910
30: Kikta DG. Thoracic root pain in diabetes: the spectrum of clinical and electromyographic findings. Ann Neurol 1982;11:80-5. PMID 7059131
31: Kilfoyle D, Kelkar P, Parry GJ. Pulsed methylprednisolone is a safe and effective treatment for diabetic amyotrophy. J Clin Neuromusc Dis 2003;4(4):168-70.
32: Koga M, Otsuki M, Kubo M, Hashimoto J, Kasayama S. Relationship between circulating vascular cell adhesion molecule-1 and microvascular complications in type 2 diabetes mellitus. Diabet Med 1998;15(8):661-7. PMID 9702469
33: Krendel DA, Castigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995;52:1053-61. PMID 7487556
34: Llewelyn JG, Thomas PK, King RH. Epineurial microvasculitis in proximal diabetic neuropathy. J Neurol 1998;245:59-65. PMID 9553846
35: Meerwaldt R, Links TP, Graaff R, et al. Increased accumulation of skin advanced glycation end products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 2005;48(8):1637-44. PMID 16021416
36: Misur I, Zarkovic K, Barada A, Batelja L, Milicevic Z, Turk Z. Advanced glycation endproducts in peripheral nerve in type 2 diabetes with neuropathy. Acta Diabetol 2004;41(4):158-66. PMID 15660198
37: Nie Q, Fan J, Haraoka S, Shimokama T, Watanabe T. Inhibition of mononuclear cell recruitment in aortic intima by treatment with anti-ICAM-1 and anti-LFA-1 monoclonal antibodies in hypercholesterolemic rats: implications of the ICAM-1 and LFA-1 pathway in atherogenesis. Lab Invest 1997;77:469-82. PMID 9389790
38: Ogawa T, Taguchi T, Tanaka Y, Ikeguchi K, Nakano I. Intravenous immunoglobulin therapy for diabetic amyotrophy. Intern Med 2001;40:349-52. PMID 11334398
39: Pascoe MK. Subacute diabetic proximal neuropathy. Mayo Clin Proc 1997;72:1123-32. PMID 9413291
40: Pinto MV, Ng PS, Howe BM, et al. Lumbosacral radiculoplexus neuropathy: neurologic outcomes and survival in a population-based atudy. Neurology 2021;96:e2098-108. PMID 33653898
41: Pinto MV, Ng PS, Laughlin RS, et al. Risk factors for lumbosacral radiculoplexus neuropathy. Muscle Nerve 2022;65(5):593-8. PMID 34970748
42: Aragon Pinto C, Pinto MV, Engelstad JK, Dyck PJ. Lumbosacral radiculoplexus neuropathy after COVID-19. Neurologist 2023;28(4):273-6. doi: 10.1097/NRL.0000000000000481. PMID: 36728648
43: Raff MC, Sangalang V, Asbury AK. Ischemic mononeuropathy multiplex associated with diabetes mellitus. Arch Neurol 1968;18:487-99. PMID 5647941
44: Said G, Elgrably F, Lacroix C, et al. Painful proximal diabetic neuropathy: inflammatory nerve lesions and spontaneous favourable outcome. Ann Neurol 1997;41:762-70. PMID 9189037
45: Said G, Goulon-Goeau C, Lacroix C, Moulonguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol 1994;35:559-69. PMID 8179302
46: Said G, Lacroix C, Lozeron P, Ropert A, Plante V, Adams D. Inflammatory vasculopathy in multifocal diabetic neuropathy. Brain 2003;126:376-85. PMID 12538404
47: Satoh J, Yagihashi S, Toyota T. The possible role of tumor necrosis factor-alpha in diabetic polyneuropathy. Exp Diabesity Res 2003;4(2):65-71. PMID 14630568
48: Sharma KR, Cross J, Ayyar DR, Martinez-Arizala A, Bradley WG. Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch Neurol 2002a;59:751-7. PMID 12020256
49: Sharma KR, Cross J, Farronay O, Ayyar DR, Shebert RT, Bradley WG. Demyelinating neuropathy in diabetes mellitus. Arch Neurol 2002b;59:758-65. PMID 12020257
50: Stewart JD. Diabetic truncal neuropathy: topography of the sensory deficit. Ann Neurol 1989;25:233-8. PMID 2729914
51: Streib EW, Sun SF, Paustian FF, Gallagher TF, Shipp JC, Ecklund RE. Diabetic thoracic radiculopathy: electrodiagnostic study. Muscle Nerve 1986;9:548-53. PMID 2942773
52: Subramony SH, Wilbourn AJ. Diabetic proximal neuropathy: clinical and electromyographic studies. J Neurol Sci 1982;53:293-304. PMID 7057213
53: Sun SF. Diabetic thoracoabdominal neuropathy: clinical and electrodiagnostic features. Ann Neurol 1981;9:75-9. PMID 6452086
54: Younger DS, Rosoklija G, Hays AP, et al. Diabetic peripheral neuropathy: a clinicopathologic and immunohistochemical analysis of sural nerve biopsies. Muscle Nerve 1996;19:722-7. PMID 8609922

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Aziz I Shaibani MD

Dr. Shaibani of Baylor College of Medicine has no relevant financial relationships to disclose.
See Profile
Duaa Jabari MD

Dr. Jabari of the University of Kansas Medical Center has no relevant financial relationships to disclose.
See Profile

Editor

Louis H Weimer MD

Dr. Weimer of Columbia University has no relevant financial relationships to disclose.
See Profile

Former Authors

Pankaj Satija MD FCPS

Patient Profile

Age range of presentation: 19 to 65+ years
Sex preponderance: male>female, >1:1
Heredity: heredity may be a factor
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Diabetes with neurological manifestations: 250.6
ICD-10: Insulin-dependent diabetes mellitus with neurologic complications: E10.4

Non-insulin-dependent diabetes mellitus with neurologic complications: E11.4

Malnutrition-related diabetes mellitus with neurologic complications: E12.4

Other specified diabetes mellitus with neurologic complications: E13.4

Unspecified diabetes mellitus with neurologic complications: E14.4
OMIM: Diabetes mellitus, insulin-dependent: +222100

Diabetes mellitus, noninsulin-dependent: #125853

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Diabetic amyotrophy

Associated Disorders

Chronic inflammatory demyelinating polyneuropathy
Diabetic autonomic neuropathy
Diabetic femoral neuropathy
Diabetic myelopathy
Diabetic truncal radiculoneuropathy
- Multifocal diabetic neuropathy
- Non-diabetic lumbosacral radiculoplexus neuropathy
- Sensorimotor polyneuropathy

Differential Diagnosis

systemic vasculitis
isolated peripheral nerve vasculitis
chronic inflammatory demyelinating polyradiculoneuropathy
compressive lumbosacral plexus lesions
quadriceps myopathies

Also Relevant

Chronic inflammatory demyelinating polyradiculoneuropathy
Diabetic neuropathies
Lumbosacral plexus injuries
Neuromuscular pathology: overview
Vasculitic neuropathies

Diabetic amyotrophy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 1. Clinical Differences Between Diabetic Amyotrophy and Diabetic Polyneuropathy

Table 2. Comparison Between Diabetic and Non-Diabetic Lumbosacral Radiculoplexus Neuropathy

Table 3. Pathological Analysis of Nerve Biopsies From Patients With Diabetic Amyotrophy, Diabetic Polyneuropathy, and Healthy Controls

Epidemiology

Table 4. Classification of Diabetic Neuropathies

Differential diagnosis

Ongoing issues about CIDP development in diabetic patients.

Table 5. Response of DM-CIDP and I-CIDP to Treatments

Table 6. American Academy of Neurology Research Criteria for the Diagnosis of CIDP

Conclusions about CIDP in diabetes mellitus.

Diagnostic workup

Management

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Familial dysautonomia

Peripheral nerve complications of HIV-1 infection

Neuropathies associated with cytomegalovirus infection

Disulfiram neuropathy

Mercury neuropathy

Clinical evaluation of peripheral neuropathies

Carpal tunnel syndrome

This is an article preview.
Start a Free Account
to access the full version.